In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Intec Pharma Ltd (NTEC – Research Report), with a price target of $15. The company’s shares opened today at $8.20.
“We view the PK results as highly encouraging, reinforcing our confidence in ACCORDANCE’s outcome (data mid-2019).”
According to TipRanks.com, Higgins has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.9% and a 33.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
Intec Pharma Ltd has an analyst consensus of Strong Buy, with a price target consensus of $15, representing an 82.9% upside. In a report issued on February 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $16 price